More Favorable Metabolic Impact of Three-Times-Weekly versus Daily Growth Hormone Treatment in Naïve GH-Deficient Children

Table 1

Clinical and biochemical features of patients grouped according to the GH treatment regimen (group A and group B) at baseline and after 12 months of treatment.

	7 doses per week; (group A); 16 patients; baseline	7 doses per week; (group A); 16 patients; 12 months		3 doses per week; (group B); 16 patients; baseline	3 doses per week; (group B); 16 patients; 12 months
	Mean ± SD	Mean ± SD	p	Mean ± SD	Mean ± SD	p
Height (SD)	−2.06 ± 0.43	−1.5 ± 0.40	<0.001	−2.04 ± 0.69	−1.5 ± 0.5	<0.001
BMI (SD)	−0.46 ± 0.48	−0.45 ± 1.3	0.876	−0.79 ± 0.45	−0.86 ± 0.8	0.052
Waist circumference (cm)	60.5 ± 10.4	62 ± 10	0.317	60.1 ± 9.0	61.5 ± 7.0	0.463
Growth velocity (SD)	−3.4 ± 0.9	2.7 ± 1.7	0.003	−3.3 ± 0.9	3 ± 1.4	<0.001
Bone/chronological age ratio	0.81 ± 0.12	0.90 ± 0.05	0.089	0.81 ± 0.09	0.89 ± 0.11	0.098
IGF-I (μg/L)	99.5 ± 23.8	332 ± 125	<0.001	100 ± 23.4	352 ± 89.1	<0.001

SD: standard deviation; BMI: body mass index.